NICE-话题@MedSci

#NICE#

226篇内容 | 5142人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1289060, encodeId=5ca5128906020, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2019 NICE指南：成人临床关怀（NG.142）, objectType=article, longId=181428, objectId=63e8181428db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63e8181428db, replyNumber=0, likeNumber=34, createdTime=2019-10-18, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63e8181428db, moduleTitle=2019 NICE指南：成人临床关怀（NG.142）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63e8181428db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289059, encodeId=dd1c128905996, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准将戊糖多硫酸钠（Elmiron）用于治疗间质性膀胱炎, objectType=article, longId=181140, objectId=f0381811408d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0381811408d, replyNumber=0, likeNumber=60, createdTime=2019-10-16, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0381811408d, moduleTitle=英国NICE批准将戊糖多硫酸钠（Elmiron）用于治疗间质性膀胱炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0381811408d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289058, encodeId=4007128905868, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2019 NICE诊断指南：类风湿性关节炎TNF-α抑制剂治疗监测（DG.36）, objectType=article, longId=180767, objectId=2da8180e67c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2da8180e67c7, replyNumber=0, likeNumber=0, createdTime=2019-10-10, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2da8180e67c7, moduleTitle=2019 NICE诊断指南：类风湿性关节炎TNF-α抑制剂治疗监测（DG.36）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2da8180e67c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289057, encodeId=7364128905e07, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, objectType=article, longId=180564, objectId=58f6180564c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f6180564c6, replyNumber=0, likeNumber=59, createdTime=2019-10-07, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f6180564c6, moduleTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f6180564c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289056, encodeId=1ba4128905692, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=每年5000英镑的治疗费用，诺华Erenumab偏头痛药物未达到NICE推荐标准, objectType=article, longId=180137, objectId=a97d18013e74, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a97d18013e74, replyNumber=0, likeNumber=73, createdTime=2019-09-29, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a97d18013e74, moduleTitle=每年5000英镑的治疗费用，诺华Erenumab偏头痛药物未达到NICE推荐标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a97d18013e74)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289055, encodeId=15691289055c6, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将诺华的Luxturna基因疗法用于治疗双等位RPE65突变引起的视力丧失, objectType=article, longId=178918, objectId=0b251e891861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b251e891861, replyNumber=0, likeNumber=74, createdTime=2019-09-07, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b251e891861, moduleTitle=NICE推荐将诺华的Luxturna基因疗法用于治疗双等位RPE65突变引起的视力丧失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b251e891861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289054, encodeId=3df812890544f, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗, objectType=article, longId=177327, objectId=749f1e732700, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749f1e732700, replyNumber=0, likeNumber=63, createdTime=2019-08-11, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749f1e732700, moduleTitle=NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=749f1e732700)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289053, encodeId=8f081289053b5, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将Keytruda与化疗联合用于治疗转移性鳞状非小细胞肺癌, objectType=article, longId=177325, objectId=b2e51e7325ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2e51e7325ae, replyNumber=0, likeNumber=80, createdTime=2019-08-11, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2e51e7325ae, moduleTitle=NICE推荐将Keytruda与化疗联合用于治疗转移性鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2e51e7325ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289052, encodeId=20d6128905236, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, objectType=article, longId=175681, objectId=3cfe1e5681e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cfe1e5681e2, replyNumber=0, likeNumber=73, createdTime=2019-07-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cfe1e5681e2, moduleTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cfe1e5681e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289051, encodeId=fbed1289051e1, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=74, createdTime=2019-07-15, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289050, encodeId=b9b7128905051, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性, objectType=article, longId=175117, objectId=a1811e511786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1811e511786, replyNumber=0, likeNumber=64, createdTime=2019-07-12, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1811e511786, moduleTitle=英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1811e511786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289049, encodeId=04ac128904965, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, objectType=article, longId=174938, objectId=c1da1e4938eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e4938eb, replyNumber=0, likeNumber=90, createdTime=2019-07-08, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e4938eb, moduleTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e4938eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289048, encodeId=32a8128904825, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐将辉瑞的Vizimpro用于治疗EGFR阳性的非小细胞肺癌患者, objectType=article, longId=174933, objectId=51dc1e4933dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51dc1e4933dc, replyNumber=0, likeNumber=83, createdTime=2019-07-08, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51dc1e4933dc, moduleTitle=英国NICE推荐将辉瑞的Vizimpro用于治疗EGFR阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51dc1e4933dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289047, encodeId=086d128904ed7, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制, objectType=article, longId=167613, objectId=b87a16e61344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b87a16e61344, replyNumber=0, likeNumber=66, createdTime=2019-06-05, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b87a16e61344, moduleTitle=英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b87a16e61344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289046, encodeId=0cf8128904671, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, objectType=article, longId=165339, objectId=4a3216533980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a3216533980, replyNumber=0, likeNumber=70, createdTime=2019-05-05, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a3216533980, moduleTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a3216533980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289045, encodeId=51661289045d2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐Akice公司的反义寡核苷酸药物Tegsedi用于治疗罕见遗传病：转甲状腺素相关的淀粉样蛋白变性, objectType=article, longId=164501, objectId=d2851645017f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2851645017f, replyNumber=0, likeNumber=56, createdTime=2019-04-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2851645017f, moduleTitle=英国NICE推荐Akice公司的反义寡核苷酸药物Tegsedi用于治疗罕见遗传病：转甲状腺素相关的淀粉样蛋白变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2851645017f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289044, encodeId=08e5128904494, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌, objectType=article, longId=164062, objectId=b2ee164062f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ee164062f7, replyNumber=0, likeNumber=69, createdTime=2019-04-12, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ee164062f7, moduleTitle=诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ee164062f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289043, encodeId=eb6f128904320, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy, objectType=article, longId=163715, objectId=a607163e15bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a607163e15bb, replyNumber=0, likeNumber=54, createdTime=2019-04-07, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a607163e15bb, moduleTitle=英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a607163e15bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289042, encodeId=7133128904239, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐礼来的Verzenio用作乳腺癌延迟药物, objectType=article, longId=163504, objectId=5b3816350403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3816350403, replyNumber=0, likeNumber=0, createdTime=2019-04-04, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3816350403, moduleTitle=英国NICE推荐礼来的Verzenio用作乳腺癌延迟药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3816350403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289041, encodeId=99dc128904164, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=由于定价过高，英国NICE拒绝了BioMarin的Batten疾病治疗药物, objectType=article, longId=160827, objectId=25b316082e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b316082e05, replyNumber=0, likeNumber=76, createdTime=2019-02-24, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b316082e05, moduleTitle=由于定价过高，英国NICE拒绝了BioMarin的Batten疾病治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b316082e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NICE

2020-05-29

fusion (审核中...)

前往app查看评论内容

#NICE#

2019 NICE指南：成人临床关怀（NG.142）

2019-10-18

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准将戊糖多硫酸钠（Elmiron）用于治疗间质性膀胱炎

2019-10-16

fusion (审核中...)

前往app查看评论内容

#NICE#

2019 NICE诊断指南：类风湿性关节炎TNF-α抑制剂治疗监测（DG.36）

2019-10-10

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say

2019-10-07

fusion (审核中...)

前往app查看评论内容

#NICE#

每年5000英镑的治疗费用，诺华Erenumab偏头痛药物未达到NICE推荐标准

2019-09-29

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将诺华的Luxturna基因疗法用于治疗双等位RPE65突变引起的视力丧失

2019-09-07

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗

2019-08-11

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将Keytruda与化疗联合用于治疗转移性鳞状非小细胞肺癌

2019-08-11

fusion (审核中...)

前往app查看评论内容

#NICE#

诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌

2019-07-19

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2019-07-15

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性

2019-07-12

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌

2019-07-08

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐将辉瑞的Vizimpro用于治疗EGFR阳性的非小细胞肺癌患者

2019-07-08

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制

2019-06-05

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌

2019-05-05

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐Akice公司的反义寡核苷酸药物Tegsedi用于治疗罕见遗传病：转甲状腺素相关的淀粉样蛋白变性

2019-04-19

fusion (审核中...)

前往app查看评论内容

#NICE#

诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌

2019-04-12

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy

2019-04-07

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐礼来的Verzenio用作乳腺癌延迟药物

2019-04-04

heli0118 (审核中...)

前往app查看评论内容

#NICE#

由于定价过高，英国NICE拒绝了BioMarin的Batten疾病治疗药物

2019-02-24

科室
- - 订阅+
  - 更多科室
工具
服务